HC Wainwright Has Positive Outlook for IKT Q1 Earnings

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) – Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of Inhibikase Therapeutics in a research note issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.10) per share for the quarter, up from their previous forecast of ($0.12). HC Wainwright has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.47) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.59) EPS.

A number of other equities research analysts have also issued reports on IKT. Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. Wall Street Zen raised Inhibikase Therapeutics to a “sell” rating in a report on Saturday, December 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Thursday, January 22nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Inhibikase Therapeutics in a report on Monday, December 29th. Finally, Bank of America initiated coverage on Inhibikase Therapeutics in a report on Wednesday, January 21st. They issued a “buy” rating and a $6.00 price target for the company. Four analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $5.50.

Inhibikase Therapeutics Trading Down 0.6%

Shares of NASDAQ:IKT opened at $1.80 on Wednesday. The firm has a market cap of $135.32 million, a PE ratio of -3.75 and a beta of 0.86. The company has a fifty day simple moving average of $1.78 and a 200 day simple moving average of $1.68. Inhibikase Therapeutics has a 12-month low of $1.33 and a 12-month high of $2.37.

Inhibikase Therapeutics (NASDAQ:IKT) last released its earnings results on Thursday, March 26th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03.

Hedge Funds Weigh In On Inhibikase Therapeutics

Institutional investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP bought a new stake in shares of Inhibikase Therapeutics in the 4th quarter worth approximately $1,094,000. Virtu Financial LLC lifted its stake in Inhibikase Therapeutics by 70.1% in the fourth quarter. Virtu Financial LLC now owns 22,869 shares of the company’s stock valued at $47,000 after buying an additional 9,423 shares during the last quarter. ADAR1 Capital Management LLC lifted its stake in Inhibikase Therapeutics by 53.7% in the fourth quarter. ADAR1 Capital Management LLC now owns 8,063,949 shares of the company’s stock valued at $16,531,000 after buying an additional 2,816,346 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Inhibikase Therapeutics during the fourth quarter valued at $42,000. Finally, Squadron Capital Management LLC acquired a new position in shares of Inhibikase Therapeutics during the fourth quarter valued at $8,661,000. 3.81% of the stock is owned by institutional investors.

Key Stories Impacting Inhibikase Therapeutics

Here are the key news stories impacting Inhibikase Therapeutics this week:

• Positive Sentiment: HC Wainwright raised several near-term estimates and lifted FY2026 EPS to ($0.47) from ($0.52), reflecting a slightly improved earnings outlook for the coming year. The analyst also increased Q1–Q3 2026 estimates (Q1 to $‑0.10, Q2 to $‑0.11, Q3 to $‑0.12). These upward revisions can be read as a sign of modest operational or modeling improvements. HC Wainwright raises FY2026 estimate
• Positive Sentiment: HC Wainwright reiterated a “Strong‑Buy” rating while publishing multi-quarter and FY2027 forecasts (FY2027 EPS at $‑0.59), which supports continued analyst conviction in the company’s longer-term prospects despite near-term losses. HC Wainwright reiterates Strong-Buy
• Neutral Sentiment: HC Wainwright released a full set of quarterly projections out to Q4 2027 (Q1–Q4 2026/2027 schedules included), which provides updated modeling inputs for investors but contains no operational guidance from the company itself. Use these estimates to update valuation and runway scenarios. HC Wainwright issues multi-year projections
• Negative Sentiment: Despite the upward revisions, all forecasts remain negative (losses per share each quarter and FY2027 EPS of $‑0.59), underscoring that Inhibikase is expected to continue operating unprofitable in the medium term — a risk for investors focused on near-term profitability or cash burn. Model still projects losses through 2027

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.